A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know
This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 months.
Overview
Scott L. Burrows, the chief financial officer of Spyre Therapeutics, Inc. (NASDAQ:SYRE), sold 7,500 shares of common stock on August 3, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($95.57); post-transaction value based on August 3 market close ($94.93).
Details
Spyre Therapeutics represents a clinical-stage biotechnology enterprise with a $9.1 billion market capitalization. The company's strategic focus on a4β7 integrin targeting positions it within a validated therapeutic pathway for IBD treatment, leveraging established mechanisms of action to address significant unmet medical needs in inflammatory bowel disease management. With 102 employees based in Waltham, Spyre is positioned to pursue clinical development and potential regulatory approval of its lead candidate for a substantial addressable market.
Source
Originally published at www.fool.com.